PD3-2-6: Interim safety results from the East/South East (E/SE) Asian subgroup of the open-label TRUST (TaRceva lUng cancer Survival Treatment) study of erlotinib for advanced non-small-cell lung cancer (NSCLC)

Abstract

S464to the extremes of ranges, and start date for length of survival: method 1. progression after second line therapy or three weeks post last dose of chemo for control group and start date of erlotinib for treatment group; method 2. last date of second line therapy for both groups. 75 control and 70 erlotinib patients were included in the analysis. Results are presented in the table. The Incremental Cost-Effectiveness Ratio (ICER) was $28,516 per life-year-gained under method 1, and $17,632 under method 2. The erlotinib group had similar one year OS compared to literature (36 vs. 31%). Method 1: Parameter Controls (N=75) Erlotinib (N=70) Area under curve (months) 3.86 7.91 p-value (log-rank test) <0.001 Median Survival months (95% CI) 2.56 (2.04-4.8) 4.73 (2.89-14.7) 1-year OS % (95% CI) 0.

Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer

“…Interim safety data from TRUST confirm the favorable safety profile of erlotinib observed in the BR.21 trial, and preliminary efficacy data are promising (disease control rate 68% and median PFS 13 weeks) [63]. Analyses of the European [64] and East/South East Asian subgroups [65] of the TRUST trial also support the safety profile observed for erlotinib in previous trials.…”